Figure legends lists
Figure 1. Flowchart of patient selection
Figure 2. The progression-free survival (PFS) curves of patients with baseline HBV DNA level ≤2000IU/mL and those with DNA level > 2000IU/mL receiving anti-PD-1 in combination with antiangiogenic therapy
Figure 3. Univariate and multivariate cox analyses of progression-free survival (PFS) stratified by baseline characteristics
Figure 4. Among the 70 patients, 2 had HBV reactivation. A. Characteristics of the 2 patients with HBV reactivation; B. Kinetics of HBV DNA in the 2 patients with HBV reactivation